Feb 6, 2024 · OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein. Here we present results from a phase 1 study of OMO-103 in advanced solid tumors, established to examine safety and...

Oct 28, 2019 · Taken together, our data suggest that the mechanism of action of Omomyc is to bind DNA as either a homodimer or a heterodimer with Max that is formed cotranslationally, revealing a novel mechanism to inhibit the MYC oncogene.

Nov 11, 2022 · Omomyc — a cell-penetrating peptide now renamed OMO-103 — appears safe and potentially effective in humans, they reported at the EORTC-NCI-AACR triple meeting in Barcelona. In the small phase I...

Omomyc mini-protein is a dominant-negative form of MYC that is used to inhibit MYC for research purposes but was thought to be too unwieldy for in vivo therapy. However, Beaulieu et al. discovered that Omomyc can penetrate into cancer cells in vitro and in vivo.

Omomyc treatment appears to rebalance the Myc/Max ratio by binding both Myc and Max proteins and preventing their interaction. Omomyc can function like Mad1, where it preferentially forms dimers with Max and represses Myc-mediated transcription (13 – 18).

Omomyc was fused with a functional penetrating “phylomer” peptide (FPPa) as a therapeutic strategy to inhibit Myc in triple-negative breast cancer (FPPa-OmoMYC; Wang et al., 2019).

Apr 4, 2020 · The recently described therapeutic effect of purified Omomyc mini-protein-following the surprising discovery of its cell-penetrating capacity-constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic.

Oct 17, 2016 · OmoMYC attenuates both MYC-dependent activation and repression by competing with MYC/MAX for binding to chromatin, effectively lowering MYC/MAX occupancy at its cognate binding sites....

Omomyc selectively targets Myc protein interactions: it binds c- and N-Myc, Max and Miz-1, but does not bind Mad or select HLH proteins. Specifically, it prevents Myc binding to promoter E-boxes and transactivation of target genes while retaining Miz-1 dependent binding to promoters and transrepression.

Oct 26, 2022 · Developed in-house by Laura Soucek’s Models of Cancer Therapies Group and VHIO-ICREA spin-off Peptomyc SL, OMO-103 targets the MYC oncogene which is deregulated in most tumor types. To date, no drug that inhibits MYC has been approved for clinical use.